Skip to main content
. Author manuscript; available in PMC: 2024 May 15.
Published in final edited form as: Circulation. 2023 Nov 30;149(1):e1–e156. doi: 10.1161/CIR.0000000000001193

Recommendations for CKD/Kidney Failure

Referenced studies that support the recommendations are summarized in the Online Data Supplement.

COR LOE Recommendations
1 B-R 1. For patients with AF at elevated risk for stroke and CKD stage 3, treatment with warfarin or, preferably, evidence-based doses of direct thrombin or factor Xa inhibitors (Table 19) is recommended to reduce the risk of stroke.13
2a B-NR 2. For patients with AF at elevated risk for stroke and CKD stage 4, treatment with warfarin or labeled doses of DOACs is reasonable to reduce the risk of stroke.4,5
2b B-NR 3. For patients with AF at elevated risk for stroke and who have end-stage CKD (CrCl <15 mL/min) or are on dialysis, it might be reasonable to prescribe warfarin (INR 2.0–3.0) or an evidence-based dose of apixaban for oral anticoagulation to reduce the risk of stroke.6,7